Knut Teigen's picture

Knut Teigen

  • E-mailKnut.Teigen@uib.no
  • Phone+47 55 58 63 28
  • Visitor Address
    Jonas Lies vei 91
    5009 Bergen
  • Postal Address
    Postboks 7804
    5020 Bergen

I am Professor at the Department of Biomedicine, University of Bergen, Norway and PI in the Metabolism and Cancer group. Our research aims to understand molecular interactions at the atomic level and the nuanced relationships between structure, dynamics and function of biomolecules. We develop and apply computational methods to simulate molecular motions, complementing experimental observations. Through collaboration with groups that develop the Amber software package for molecular simulations, we have developed the Amber force field to simulate molecular interactions of lipid complexes. With the Amber lipid force field, we are currently able to simulate complex molecular systems of any composition. We apply these methods to understand the function of large molecular systems based on intermolecular forces and inherent dynamics. Our force field development is also relevant to methods for virtual screening of compound databases against any macromolecular target and integrates well with the experimental screening of small compounds at the Department of Biomedicine. I am cofounder and shareholder of the company Pluvia Pharma AS, a startup biotech company in Bergen that seeks to develop small molecule pharmacological chaperones with potential to correct protein misfolding diseases.

I am member of the Program Commitee for medical education at UiB and responsible for the second semester of medical school. I teach subjects in biochemistry and cell biology for pharmacy, dentistry, and medical students and am also involved in teaching structural biology as part of master's and PhD courses at the Department of Biomedicine. I offer master's projects for students in pharmacy, nanoscience, biomedicine, and medical technology, as well as projects for the research program in medicine. Through the Federation of European Biochemical Societies (FEBS), I am involved in the development of biochemistry education and participate in FEBS forums as the Norwegian ambassador for biochemistry education.

When not teaching biochemistry I am very passionate about skiing and am part of the educational board of Snowsports Norway where I am involved in education and international certification of snowsport instructors.

Academic article
  • Show author(s) (2022). Structural mechanism for tyrosine hydroxylase inhibition by dopamine and reactivation by Ser40 phosphorylation. Nature Communications.
  • Show author(s) (2022). Modeling of mutant superoxide dismutase 1 octamers with cross-linked disulfide bonds. Journal of Molecular Modeling. 1-7.
  • Show author(s) (2022). Inhibition of VMAT2 by β2-adrenergic agonists, antagonists, and the atypical antipsychotic ziprasidone. Communications Biology. 1-14.
  • Show author(s) (2021). Synthetic corticosteroids as tryptophan hydroxylase stabilizers. Future Medicinal Chemistry. 1465-1474.
  • Show author(s) (2021). Investigating the Disordered and Membrane-Active Peptide A-Cage-C Using Conformational Ensembles. Molecules. 3607.
  • Show author(s) (2020). The Arabidopsis (ASHH2) CW domain binds monomethylated K4 of the histone H3 tail through conformational selection. The FEBS Journal. 4458-4480.
  • Show author(s) (2020). Levalbuterol lowers the feedback inhibition by dopamine and delays misfolding and aggregation in tyrosine hydroxylase. Biochimie.
  • Show author(s) (2020). Inhibition of Tryptophan Hydroxylases and Monoamine Oxidase-A by the Proton Pump Inhibitor, Omeprazole—In Vitro and In Vivo Investigations. Frontiers in Pharmacology.
  • Show author(s) (2020). Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. Cancer Research. 2163-2174.
  • Show author(s) (2020). Discovery and biological characterization of a novel scaffold for potent inhibitors of peripheral serotonin synthesis. Future Medicinal Chemistry. 1461-1474.
  • Show author(s) (2019). Dominant ARL3-related retinitis pigmentosa. Ophthalmic Genetics. 124-128.
  • Show author(s) (2019). Characterization of the interaction of the antifungal and cytotoxic cyclic glycolipopeptide hassallidin with sterol-containing lipid membranes. Biochimica et Biophysica Acta - Biomembranes. 1510-1521.
  • Show author(s) (2017). Substituting Tyr138 in the active site loop of human phenylalanine hydroxylase affects catalysis and substrate activation. FEBS Open Bio. 1026-1036.
  • Show author(s) (2017). Cripto stabilizes GRP78 on the cell membrane. Protein Science. 653-661.
  • Show author(s) (2016). Simulation of lipid bilayer self-assembly using all-atom lipid force fields. Physical Chemistry, Chemical Physics - PCCP. 10573-10584.
  • Show author(s) (2015). Mammalian CSAD and GADL1 have distinct biochemical properties and patterns of brain expression. Neurochemistry International. 173-184.
  • Show author(s) (2015). Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms. Biochimica et Biophysica Acta - Proteins and Proteomics. 1078-1089.
  • Show author(s) (2015). All-atom lipid bilayer self-assembly with the AMBER and CHARMM lipid force fields. Chemical Communications. 4402-4405.
  • Show author(s) (2014). The N-terminal sequence of tyrosine hydroxylase is a conformationally versatile motif that binds 14-3-3 proteins and membranes. Journal of Molecular Biology (JMB). 150-168.
  • Show author(s) (2014). Lipid14: The amber lipid force field. Journal of Chemical Theory and Computation. 865-879.
  • Show author(s) (2014). Introduction of aromatic ring-containing substituents in cyclic nucleotides is associated with inhibition of toxin uptake by the hepatocyte transporters OATP 1B1 and 1B3. PLOS ONE.
  • Show author(s) (2013). Screening and evaluation of small organic molecules as ClpB inhibitors and potential antimicrobials. Journal of Medicinal Chemistry. 7177-7189.
  • Show author(s) (2013). Iodinin (1,6-dihydroxyphenazine 5,10-dioxide) from streptosporangium sp. induces apoptosis selectively in myeloid leukemia cell lines and patient cells. Marine Drugs. 332-349.
  • Show author(s) (2013). Inhibition of sorbitol dehydrogenase by nucleosides and nucleotides. Biochemical and Biophysical Research Communications - BBRC. 202-208.
  • Show author(s) (2012). LIPID11: A modular framework for lipid simulations using amber. Journal of Physical Chemistry B. 11124-11136.
  • Show author(s) (2011). The regulatory subunit of PKA-I remains partially structured and undergoes beta-aggregation upon thermal denaturation. PLOS ONE. 10 pages.
  • Show author(s) (2011). Substrate Hydroxylation by the Oxido-Iron Intermediate in Aromatic Amino Acid Hydroxylases: A DFT Mechanistic Study. European Journal of Inorganic Chemistry (EurJIC). 2720-2732.
  • Show author(s) (2011). Intramolecular hydrogen bonding in articaine can be related to superior bone tissue penetration: A molecular dynamics study. Biophysical Chemistry. 18-25.
  • Show author(s) (2011). Formation of the Iron-Oxo Hydroxylating Species in the Catalytic Cycle of Aromatic Amino Acid Hydroxylases. Chemistry - A European Journal. 3746-3758.
  • Show author(s) (2011). Conformational sampling and nucleotide-dependent transitions of the GroEL subunit probed by unbiased molecular dynamics simulations. PLoS Computational Biology.
  • Show author(s) (2011). Binding of ATP at the active site of human pancreatic glucokinase - nucleotide-induced conformational changes with possible implications for its kinetic cooperativity. The FEBS Journal. 2372-2386.
  • Show author(s) (2010). Superstoichiometric binding of L-Phe to phenylalanine hydroxylase from Caenorhabditis elegans: evolutionary implications. Amino Acids. 1463-1475.
  • Show author(s) (2009). Overview of computational methods employed in early-stage drug discovery. Future Medicinal Chemistry. 49-63.
  • Show author(s) (2009). Evolution of regulation, structure and function in phenylalanine hydroxylase. Pteridines. 42-50.
  • Show author(s) (2007). A simple method to calculate the accessible volume of protein-bound ligands: Application for ligand selectivity. Journal of Molecular Graphics and Modelling. 429-433.
  • Show author(s) (2006). Specific interaction of the diastereomers 7(R)- and 7(S)-tetrahydrobiopterin with phenylalanine hydroxylase: implications for understanding primapterinuria and vitiligo. The FASEB Journal. 2130-2132.
  • Show author(s) (2006). Epac1 and cAMP-dependent protein kinase holoenzyme have similar cAMP affinity, but their cAMP domains have distinct structural features and cyclic nucleotide recognition. Journal of Biological Chemistry. 21500-21511.
  • Show author(s) (2005). The reaction mechanism of phenylalanine hydroxylase. A question of coordination. Pteridines. 27-34.
  • Show author(s) (2004). Thermodynamic characterization of the binding of tetrahydropterins to phenylalanine hydroxylase . Journal of the American Chemical Society. 13670-13678.
  • Show author(s) (2004). Tetrahydrobiopterin binding to aromatic amino acid hydroxylases. Ligand recognition and specificity. Journal of Medicinal Chemistry. 5962-5971.
  • Show author(s) (2004). Structural and stability effects of phosphorylation � Localized structural changes in phenylalanine hydroxylase. Protein Science. 1219-1226.
  • Show author(s) (1999). The structural basis of the recognition of phenylalanine and pterin cofactors by phenylalanine hydroxylase. Implications for the catalytic mechanism. Journal of Molecular Biology (JMB). 807-823.
  • Show author(s) (1999). The structural Basis of the Recognition of Phenylalanine and Pterine Cofactors by Phenylalanine Hydroxylase. Implications for the Catalytic Mechanism. Journal of Molecular Biology (JMB). 807-823.
Academic lecture
  • Show author(s) (2009). Dioxygen in aromatic amino acid hydroxylases.
  • Show author(s) (1998). NMR study on the conformation of L-phenylalanine and dihydrobiopterin bound to wild-type and mutant forms of recombinant human phenylalanine hydroxylase.
Short communication
  • Show author(s) (2010). Water dissociation and dioxygen binding in phenylalanine hydroxylase. European Journal of Inorganic Chemistry (EurJIC). 351-356.
Masters thesis
  • Show author(s) (2016). Characterization of prevalent phenylketonuria mutations Effect of potential pharmacological chaperones .
  • Show author(s) (2015). Identification of small molecular modulators of 14-3-3 functions. A virtual screening approach with experimental validation.
  • Show author(s) (2015). Discovery of small-molecular disruptors of protein-protein inteactions A virtual screening approach applied to 14-3-3¿ and tyrosine hydroxylase.
  • Show author(s) (2014). Identification of pharmacological chaperones for Phenylalanine Hydroxylase A virtual screening approach to discover novel drug candidates for treatment of phenylketonuria.
  • Show author(s) (2012). Stabilisation of Tyrosine Hydroxylase in Nanoparticles for Enzyme Replacement Therapy.
  • Show author(s) (2011). Interactions between polychlorinated biphenyls (PCBs) and a phospholipid bilayer: A molecular dynamics study.
Doctoral dissertation
  • Show author(s) (2015). A study of Structure-Function-Stability Relationships in Tyrosine Hydroxylase.
  • Show author(s) (2004). Structural and Functional Aspects of Pterin-Binding Enzymes - A Nuclear Magnetic Resonance Spectroscopy and Molecular Modeling Study.
Academic chapter/article/Conference paper
  • Show author(s) (2014). Structure–Function Relationships in the Aromatic Amino Acid Hydroxylases Enzyme Family: Evolutionary Insights.
  • Show author(s) (2010). The aromatic amino acid hydroxylase mechanism: a perspective from computational chemistry. 64 pages.
  • Show author(s) (2012). Developing a comprehensive modular phospholipid force field for AMBER. Abstract of Papers of the American Chemical Society. 1 pages.
  • Show author(s) (2012). AMBER-Lipid 11: A new modular lipid force field for molecular dynamics. Abstract of Papers of the American Chemical Society. 1 pages.
  • Show author(s) (2022). High-throughput screening for VMAT2 activity modulators.
  • Show author(s) (2020). Searching for new inhibitors of vesicular monoamine transporter 2 by differential scanning fluorimetry.
  • Show author(s) (2020). Identification of VMAT2 inhibitory compounds.
  • Show author(s) (2010). Dioxygen Binding and Formation of the Hydroxylating FeIV=O Intermediate in Aromatic Amino Acid Hydroxylases.
  • Show author(s) (2010). Can intramolecular hydrogen bonding in articaine be related to superior bone tissue penetration? A molecular dynamics study.
  • Show author(s) (2009). Molecular dynamics simulation: Interaction between the local anaesthetic articaine and membrane models.
  • Show author(s) (2009). Catalytic cycle of phenylalanine hydroxylase.
  • Show author(s) (2009). Catalytic cycle of phenylalanine hydroxylase.
  • Show author(s) (2008). Interactions between the local anesthetic articaine and membranes: A theoretical and experiemntal study.
  • Show author(s) (2008). Interaction of a local anaesthetic with lipid membranes studied by computer modelling.
  • Show author(s) (2008). Drug-membrane interactions. An explanation for the anti-inflammatory effect of local anesthetics?
  • Show author(s) (2016). Erratum: Discovery of compounds that protect tyrosine hydroxylase activity through different mechanisms (Biochimica et Biophysica Acta - Proteins and Proteomics (2015) 1854:9 (1078-1089) DOI: 10.1016/j.bbapap.2015.04.030). Biochimica et Biophysica Acta - Proteins and Proteomics. 317.
Academic literature review
  • Show author(s) (2016). Pharmacological chaperones that protect Tetrahydrobiopterin dependent aromatic amino acid hydroxylases through different mechanisms. Current Drug Targets. 1515-1526.
  • Show author(s) (2010). The aromatic amino acid hydroxylase mechanism: A perspective from computational chemistry. Advances in Inorganic Chemistry. 437-500.
  • Show author(s) (2009). Rescuing proteins of low kinetic stability by chaperones and natural ligands; phenylketonuria, a case study. Progress in Nucleic Acid Research and Molecular Biology. 89-134.
  • Show author(s) (2007). Selectivity and affinity determinants for ligand binding to the aromatic amino acid hydroxylases. Current Medicinal Chemistry. 455-467.

More information in national current research information system (CRIStin)